Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
16.01.2024 / 17:54 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:Evotec SE
Street:Manfred Eigen Campus / Essener Bogen 7
Postal code:22419
City:Hamburg
Germany
Legal Entity Identifier (LEI):529900F9KI6OYITO9B12

>
2. Reason for notification

XAcquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
XOther reason:
voluntary group notification with triggered threshold on subsidiary level

>
3. Details of person subject to the notification obligation

Legal entity: T. Rowe Price International Funds, Inc.
City of registered office, country: Baltimore, Maryland, United States of America (USA)

>
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

T. Rowe Price International Stock Fund

>
5. Date on which threshold was crossed or reached:

12 Jan 2024

>
6. Total positions

% of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New4.84 %0.00 %4.84 %177185736
Previous notification4.95 %0.00 %4.95 %/

>
7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISINAbsoluteIn %
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0005664809085820930.00 %4.84 %
Total85820934.84 %

>
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrumentExpiration or maturity dateExercise or conversion periodVoting rights absoluteVoting rights in %
00.00 %
Total00.00 %

>
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrumentExpiration or maturity dateExercise or conversion periodCash or physical settlementVoting rights absoluteVoting rights in %
00.00 %
Total00.00 %

>
8. Information in relation to the person subject to the notification obligation

Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
XFull chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

>

Name% of voting rights (if at least 3% or more)% of voting rights through instruments (if at least 5% or more)Total of both (if at least 5% or more)
T. Rowe Price International Funds, Inc. % % %
T. Rowe Price International Stock Fund3.01 % % %
% % %
T. Rowe Price International Funds, Inc. % % %
T. Rowe Price Overseas Stock Fund % % %
% % %
T. Rowe Price International Funds, Inc. % % %
T. Rowe Price Global Growth Stock Fund % % %

>
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rightsProportion of instrumentsTotal of both
% % %

>
10. Other explanatory remarks:

>
Date

16 Jan 2024

>

16.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com



Veröffentlicht am 16.01.2024

Aktuelle Research Artikel

Biotechnologie

Defence Therapeutics vor Neubewertung? Unsere Einschätzung zum Nachrechnen

Defence Therapeutics Inc. Aktie (WKN: A3CN14): ADC-Pionier John Lambert wechselt zu Microcap Defence Therapeutics – offenbar wegen einer Lösung für das zentrale Problem: Wirkstoffe bleiben in Krebszellen stecken.
Biotechnologie

BioNxt hält den einzigen Schlüssel zu einem 2,5-Milliarden-Molekül, das keinem mehr gehört

BioNxt Solutions Inc. Aktie (WKN: A3D1K3): Ungültige Patente und Generika beenden Mercks Mavenclad-Milliardengeschäft in den USA; ab 2027 droht Europa. Der Wirkstoff dürfte dennoch weiter wachsen.
Luft- und Raumfahrtindustrie

SpaceX: Die teuerste Rakete der Börsengeschichte. Und warum wir trotzdem einsteigen würden

Space Exploration Technologies Corp. Aktie (WKN: A42D4F): SpaceX feierte 2026 den größten Börsengang der Geschichte, dominiert Raketenstarts und wächst mit Starlink rasant – trotz starker Kursschwankungen.
Automobilproduktion

Daimler Truck: Während alle zweifeln, füllen sich die Auftragsbücher

Daimler Truck Holding AG Aktie (WKN: DTR0CK): Daimler Truck dominiert den Lkw-Markt, leidet aber unter Kursverlusten trotz stark steigender Aufträge – der Markt unterschätzt die Erholung.
 Ja, ich möchte den Newsletter abonnieren!*
* Sie können sich jederzeit aus dem Newsletter heraus abmelden. Weitere Informationen zum Thema Datenschutz erhalten Sie in unserer Datenschutzerklärung